Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Clinical Gastroenterology and Hepatology

• Publication date

  2006-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.CGH.2006.06.025PMID 16931170
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.

  2007cited by this paper
• Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis

  2005cited by this paper
• Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease

  2005cited by this paper
• Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.

  2005cited by this paper
• Variability factors in the clinical response to recombinant antibodies and IgG Fc-containing fusion proteins

  2005cited by this paper
• Correlation of C‐Reactive Protein With Clinical, Endoscopic, Histologic, and Radiographic Activity in Inflammatory Bowel Disease

  2005cited by this paper
• Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.

  2004cited by this paper
• Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD.

  2004cited by this paper
• Infliximab maintenance therapy for fistulizing Crohn's disease.

  2004cited by this paper
• Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.

  2004cited by this paper
• Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.

  2004cited by this paper
• Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

  2003cited by this paper
• Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.

  2003cited by this paper
• The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial.

  2002cited by this paper
• A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease.

  2002cited by this paper
• Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

  2002cited by this paper
• Infliximab for the treatment of fistulas in patients with Crohn's disease.

  1999cited by this paper
• Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.

  1998cited by this paper
• A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

  1997cited by this paper
• A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

  1997cited by this paper
• A simple index of Crohn's-disease activity.

  1980cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Determination of correlation of clearance with clinical outcomes for inflammatory bowel disease

  2026cites this paper
• Role of miR-338-3p and miR-378a-3p as regulators in Crohn's disease pathogenesis: Potential therapeutic implications in inflammatory bowel disease.

  2026cites this paper
• Impact of non-serious infections on medication interruptions, quality of life, and disease flares in patients with rheumatoid arthritis.

  2025cites this paper
• Infliximab for patients with moderate to severely active ulcerative colitis: an updated meta-analysis of randomized controlled trials

  2025cites this paper
• Prevalence and clinical implications of anti-drug antibody formation and serum drug levels among patients with IBD receiving anti-TNF therapy: A cross-sectional study

  2025influential citation
• Therapeutic Drug Monitoring for Dose Optimization of Infliximab in Patients With Inflammatory Bowel Disease: An Analysis of Canadian Real-World Data

  2025cites this paper
• Involvement of HLADQA1*05 in Patients with Inflammatory Bowel Disease Treated with Anti-TNF Drugs

  2025cites this paper
• Is There Still a Role for Proactive Therapeutic Drug Monitoring (TDM) in Inflammatory Bowel Disease (IBD): A Review of the Literature

  2025cites this paper
• North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition position paper on the therapeutic drug monitoring in pediatric inflammatory bowel disease

  2025cites this paper
• Therapeutic Drug Monitoring of Biologics: Current Practice, Challenges and Opportunities – a Workshop Report

  2025cites this paper
• Optimizing serum adalimumab levels in maintenance therapy via proactive therapeutic drug monitoring improves markers of disease activity in Crohn’s disease

  2025cites this paper
• Infliximab Trough Levels Are Associated With Endoscopic Remission in Small Bowel Crohn's Disease.

  2024cites this paper
• Effectiveness and Tolerability of Methotrexate Combined with Biologics in Patients with Crohn’s Disease: A Multicenter Observational Study

  2024cites this paper
• Infliximab desensitization in patients with inflammatory bowel diseases: a safe therapeutic alternative

  2024cites this paper
• Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease

  2024cites this paper
• Monoclonal antibodies against pediatric ulcerative colitis: a review of clinical progress

  2024cites this paper
• Infliximab serum concentrations and disease activity in perianal fistulizing Crohn’s disease: a cross-sectional study

  2024cites this paper
• Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis

  2023cites this paper
• Factors that influence infliximab biosimilar trough levels in the pediatric inflammatory bowel disease population

  2023cites this paper
• Efficacy of Combined Initial Treatment of Methotrexate with Infliximab in Pediatric Crohn’s Disease: A Pilot Study

  2023cites this paper
• Application of a Precision‐Dosing Model to a Real‐World Cohort of Patients on Infliximab Maintenance Therapy: Drug Usage and Cost Analysis

  2023cites this paper
• Patients With Inflammatory Bowel Diseases and Higher Visceral Adipose Tissue Burden May Benefit From Higher Infliximab Concentrations to Achieve Remission

  2023cites this paper
• Development and validation of enzyme-linked immunosorbent assays for the measurement of infliximab and anti-drug antibody levels

  2023cites this paper
• THE EVALUATION OF INFLIXIMAB TROUGH LEVEL FAVORS MAINTENANCE THERAPY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE.

  2023cites this paper
• Anti-infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease.

  2023cites this paper
• Precision medicine and drug optimization in adult inflammatory bowel disease patients

  2023cites this paper
• Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment—TUMMY Study

  2023cites this paper
• Outcomes of Infliximab-Treated Inflammatory Bowel Disease Patients Undergoing Therapeutic Drug Monitoring with Two Different Assays.

  2023cites this paper
• Point-of-care therapeutic drug monitoring of tumour necrosis factor-α inhibitors using a single step immunoassay

  2023cites this paper
• A novel role of prognostic nutritional index in predicting the effectiveness of infliximab in Crohn's disease

  2023cites this paper
• Home Immunization with Palivizumab-A Randomized Pilot Study Describing Safety Aspects and Parents’ Preferences

  2023cites this paper
• Predictive value of infliximab trough levels in maintenance therapy for 5-year sustained clinical remission in patients with inflammatory bowel disease.

  2023cites this paper
• A Review of Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Receiving Combination Therapy

  2023cites this paper
• Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab

  2022cites this paper
• Short interruptions of TNF-inhibitor treatment can be associated with treatment failure in patients with immune-mediated diseases

  2022cites this paper
• The Sincerest Form of Flattery? Biosimilars in Inflammatory Bowel Disease.

  2022cites this paper
• Infliximab: a single-centre, prospective, observational evaluation of TDM data in patients with IBD

  2022cites this paper
• Adrenomedullin for biologic‐resistant Crohn's disease: A randomized, double‐blind, placebo‐controlled phase 2a clinical trial

  2022cites this paper
• Development of anti-rituximab antibodies in rituximab-treated patients: Related parameters & consequences

  2022cites this paper
• Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening

  2022cites this paper
• Dashboard-Driven Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces Immunogenicity.

  2022cites this paper
• Retreatment with anti-tumor necrosis factor therapy in combination with an immunomodulator for recurrence of Crohn’s disease after ileocecal resection results in prolonged continuation as compared to anti-tumor necrosis factor monotherapy

  2022cites this paper
• Immunosuppressants

  2022cites this paper
• Comparison of the Pharmacokinetics of CT-P13 Between Crohn’s Disease and Ulcerative Colitis

  2022cites this paper
• Pipeline Therapeutics

  2022cites this paper
• Drug-induced liver injury secondary to biologic medications in inflammatory bowel disease: meta-analysis and systematic review

  2021cites this paper
• Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?

  2021influential citation
• Bacterial Translocation as Inflammatory Driver in Crohn’s Disease

  2021cites this paper
• External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease

  2021cites this paper
• Safety, satisfaction and cost savings of accelerated infusions of standard and intensified‐dose infliximab for inflammatory bowel disease

  2021cites this paper
• Surface plasmon resonance unveils important pitfalls of enzyme-linked immunoassay for the detection of anti-infliximab antibodies in patients’ sera

  2021cites this paper
• A Novel Radiomics Nomogram for the Prediction of Secondary Loss of Response to Infliximab in Crohn’s Disease

  2021cites this paper
• Anti-Drug Antibodies in Patients with Inflammatory Bowel Diseases Treated with Biosimilar Infliximab: A Prospective Cohort Study

  2021cites this paper
• Immunogenicity of biologics used in the treatment of inflammatory bowel disease

  2021cites this paper
• The effect of infliximab dose escalation in inflammatory bowel disease patients with antibodies to infliximab

  2021cites this paper
• Payer-Directed Infusion Site Strategies Negatively Affect Outcomes in Patients With Inflammatory Bowel Disease

  2021cites this paper
• Infliximab therapy intensification based on endoscopic activity is related to suppress treatment discontinuation in patients with Crohn disease

  2021influential citation
• External Evaluation of Population Pharmacokinetic Models and Bayes-Based Dosing of Infliximab

  2021influential citation
• Postoperative Complications in Pediatric IBD Patients on Biologic Therapy Undergoing Intra-abdominal Surgery

  2021cites this paper
• 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future

  2021cites this paper
• CORRELATION BETWEEN TROUGH LEVELS OF INFLIXIMAB AND POSTOPERATIVE ENDOSCOPIC RECURRENCE IN CROHN'S DISEASE PATIENTS SUBMITTED TO ILEOCOLONIC RESECTIONS: A SYSTEMATIC REVIEW.

  2021cites this paper
• Systematic review and meta-analysis of drug induced liver injury secondary to biologic medications in inflammatory bowel disease

  2021cites this paper
• Ustekinumab induction concentrations are associated with clinical and biochemical outcomes at week 12 of treatment in Crohn’s disease

  2021cites this paper
• Discontinuation of Azathioprine could be considered in pediatric patients with Crohn’s disease who have sustained clinical and deep remission

  2021cites this paper
• Second Mexican consensus on biologic therapy and small-molecule inhibitors in inflammatory bowel disease

  2021cites this paper
• Title: Immunogenicity of biologics used in the treatment of inflammatory bowel disease

  2021cites this paper
• Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?

  2021cites this paper
• Anti‐TNF and immunosuppressive combination therapy is preferential to inducing clinical remission in patients with active inflammatory bowel disease: A systemic review and meta‐analysis

  2021cites this paper
• 25 years of biologicals in IBD: What´s all the hype about?

  2021cites this paper
• Antibodies‐to‐infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn’s disease

  2021cites this paper
• Serum trough levels of infliximab are not associated with peripheral arthralgia activity in patients with inflammatory bowel disease

  2021cites this paper
• Effect of Educational Program about Biological Therapy on Nurses Performance in Caring of Patient with Inflammatory Bowel Disease and its Activity Grade

  2021cites this paper
• Twenty‐five years of biologicals in IBD: What´s all the hype about?

  2021cites this paper
• Comparison of Timing to Develop Anti-Drug Antibodies to Infliximab and Adalimumab Between Adult and Pediatric Age Groups, Males and Females.

  2021cites this paper
• Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease

  2020cites this paper
• Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Infliximab in Pediatric Inflammatory Bowel Disease: A Systematic Review and Revised Dosing Considerations.

  2020cites this paper
• A virtual clinic increases anti‐TNF dose intensification success via a treat‐to‐target approach compared with standard outpatient care in Crohn’s disease

  2020cites this paper
• Prediction of response to biological treatment with monoclonal antibodies in severe asthma.

  2020cites this paper
• Bayes‐based dosing of infliximab in inflammatory bowel diseases: Short‐term efficacy

  2020cites this paper
• Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients

  2020cites this paper
• Clinical Immunogenicity Risk Assessment Strategy for a Low Risk Monoclonal Antibody

  2020cites this paper
• Prediction of treatment failure during infliximab induction therapy in inflammatory bowel disease patients based on pharmacokinetic and pharmacodynamic modeling.

  2020cites this paper
• Exposure–Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis

  2020cites this paper
• Pharmacokinetics, Pharmacodynamics and Immunogenicity of Infliximab in Paediatric Inflammatory Bowel Disease; a Systematic Review and Revised Dosing Considerations.

  2020cites this paper
• Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease

  2020cites this paper
• Is Therapeutic Drug Monitoring for Anti-Tumor Necrosis Factor Agents in Adults with Inflammatory Bowel Disease Ready for Standard of Care?: A Systematic Review and Meta-analysis.

  2020cites this paper
• The potential value of blood monitoring of biologic drugs used in the treatment of rheumatoid arthritis

  2020cites this paper
• Infliximab levels and antibodies in IBD-related peripheral arthralgia

  2020cites this paper
• Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab

  2020cites this paper
• Infliximab pharmacokinetics monitoring in inflammatory bowel disease.

  2020cites this paper
• Trough Levels of Infliximab at W6 Are Predictive of Remission at W14 in Pediatric Crohn Disease.

  2020cites this paper
• Optimization of azathioprine dose in combined treatment with anti-TNF-alpha in inflammatory bowel disease.

  2020cites this paper
• Does Perianal Disease Influence the Efficacy of Combination Therapy in Crohn’s Disease?

  2020cites this paper
• Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial

  2020cites this paper
• Correlation of serum levels of anti-tumor necrosis factor agents with perianal fistula healing in Crohn’s disease: a narrative review

  2020cites this paper
• Current management of fistulizing perianal Crohn’s disease based on serum anti-tumor necrosis factor levels and magnetic resonance imaging monitoring

  2020cites this paper
• Therapeutic drug monitoring of anti-tumor necrosis factor agents: lessons learned and remaining issues.

  2020cites this paper
• Assessing adherence to infusion-based biologic therapies in patients with inflammatory bowel disease.

  2020cites this paper
• Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments

  2020cites this paper
• Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring?

  2020cites this paper